Praxis Precision Medicines (PRAX)
250.33
-2.92 (1.15%)
Upcoming Events
Latest Headlines
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
June 4, 2026 4:01 PM - Globe NewsWire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026 4:01 PM - Globe NewsWire
Raymond James sees a 'unique buying opportunity' in this stock
June 2, 2026 4:00 PM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Lowered at TD Cowen Following Vormatrigine Miss
June 2, 2026 8:22 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $650 at Oppenheimer
June 2, 2026 7:40 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $616 at Truist Securities
June 2, 2026 7:05 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $1,201 at H.C. Wainwright
June 2, 2026 6:54 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $400 at Baird
June 2, 2026 6:16 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $810 at BTIG
June 2, 2026 5:03 AM - StreetInsider
Form 8-K Praxis Precision Medicin For: Jun 01
June 1, 2026 4:29 PM - SEC Filing
Praxis pauses vormatrigine study after trial misses primary endpoint
June 1, 2026 4:15 PM - StreetInsider
Praxis Precision Medicines Provides Vormatrigine Program Update
June 1, 2026 4:15 PM - Globe NewsWire
Praxis Precision Medicines (PRAX) halted, news pending
June 1, 2026 4:14 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
May 26, 2026 6:52 AM - StreetInsider
Form 4 Praxis Precision Medicin For: May 14 Filed by: Mastrocola Lauren
May 19, 2026 9:46 PM - SEC Filing
Form 4 Praxis Precision Medicin For: May 14 Filed by: Nemiroff Alex
May 19, 2026 9:45 PM - SEC Filing
Form 4 Praxis Precision Medicin For: May 14 Filed by: Kelly Timothy Edwin
May 19, 2026 9:45 PM - SEC Filing
Form 4 Praxis Precision Medicin For: May 14 Filed by: Sniecinski Megan
May 19, 2026 9:43 PM - SEC Filing
Form 4 Praxis Precision Medicin For: May 14 Filed by: Souza Marcio
May 19, 2026 9:43 PM - SEC Filing
Form SCHEDULE 13G Praxis Precision Medicin Filed by: BAKER BROS. ADVISORS LP
May 15, 2026 4:26 PM - SEC Filing
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:24 PM - SEC Filing
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: ORBIS INVESTMENT MANAGEMENT LTD
May 15, 2026 1:18 PM - SEC Filing
Form 8-K Praxis Precision Medicin For: May 07
May 13, 2026 4:17 PM - SEC Filing
Praxis Precision Medicines Inc. (PRAX) PT Raised to $715 at Truist Securities
May 13, 2026 7:15 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Raised to $550 at Jefferies
May 7, 2026 1:54 PM - StreetInsider
Form 10-Q Praxis Precision Medicin For: Mar 31
May 7, 2026 9:07 AM - SEC Filing
Praxis Precision Medicines (PRAX) Tops Q1 EPS by 40c
May 7, 2026 8:07 AM - StreetInsider
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: FMR LLC
May 6, 2026 11:36 AM - SEC Filing
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2026 4:01 PM - Globe NewsWire
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
May 4, 2026 4:01 PM - Globe NewsWire
Form DEFA14A Praxis Precision Medicin
April 30, 2026 4:26 PM - SEC Filing
Form DEF 14A Praxis Precision Medicin For: Jun 10
April 30, 2026 4:21 PM - SEC Filing
Form SCHEDULE 13G Praxis Precision Medicin Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 11:59 AM - SEC Filing
Praxis Precision Medicines Inc. (PRAX) PT Raised to $537 at Needham
April 24, 2026 8:44 AM - StreetInsider
Praxis Precision Medicines Inc. (PRAX) PT Raised to $437 at Deutsche Bank
April 15, 2026 9:39 AM - StreetInsider
Form 8-K Praxis Precision Medicin For: Apr 14
April 14, 2026 5:11 PM - SEC Filing
Jones Trading on Praxis Precision Medicines Inc. (PRAX): 'one step closer to becoming a commercial-stage company'
April 14, 2026 3:32 PM - StreetInsider
BTIG on Praxis Precision Medicines Inc. (PRAX): NDA acceptance offers clean regulatory setup for approval
April 14, 2026 11:46 AM - StreetInsider
Jefferies on Praxis Precision Medicines Inc. (PRAX): 'see 5%+ stock upside as FDA accepts the NDA for ulixacaltamide'
April 14, 2026 11:38 AM - StreetInsider
Praxis Precision Medicines receives FDA acceptance for essential tremor drug
April 14, 2026 7:30 AM - StreetInsider
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
April 14, 2026 7:30 AM - Globe NewsWire
Praxis to present ulixacaltamide essential tremor data at AAN 2026
April 13, 2026 8:01 AM - StreetInsider
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
April 13, 2026 8:00 AM - Globe NewsWire
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Raymond James Starts Praxis Precision Medicines Inc. (PRAX) at Strong Buy, 'Bears Sound Smart, but Bulls Make Money'
April 9, 2026 4:26 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
April 7, 2026 7:45 AM - StreetInsider
Form 8-K Praxis Precision Medicin For: Apr 06
April 6, 2026 4:24 PM - SEC Filing
Praxis Precision Medicines reports positive trial results for epilepsy drug
April 6, 2026 8:00 AM - StreetInsider
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
April 6, 2026 8:00 AM - Globe NewsWire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026 4:01 PM - Globe NewsWire
FDA accepts Praxis PRAX application for epilepsy drug relutrigine
March 30, 2026 4:01 PM - StreetInsider
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
March 30, 2026 4:01 PM - Globe NewsWire
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: VANGUARD GROUP INC
March 27, 2026 11:20 AM - SEC Filing
Full Article List
